cardiovascular
Home » Archives for cardiovascular
Heart-Stopping Data For Avandia And Actos
Wednesday, August 25th, 2010
Just as the FDA decides the fate of the controversial Avandia diabetes pill, a new study finds the drug has the same cardiovascular risk as the rival Actos medication. In the latest analysis, about 4 percent of patients taking either pill suffered a heart attack, heart failure, both or died over a 33-month period. The study was publish in Circulation: Cardiovascular Quality and Outcomes ( see abstract ).
Posted in: Regulatory | 0 Comments »
Read the full story
Glaxo Hid A Study On Avandia Risks For A Decade
Tuesday, July 13th, 2010
Nothing like dropping a bombshell on the morning of a crucial FDA advisory committee meeting. But GlaxoSmithKline quietly began a study in 1999 to determine if the cardiovascular risks of its Avandia diabetes pill were greater than with Actos, a similar drug, and instead of publishing the results, the drugmaker spent 11 years trying to cover them up, according to The New York Times .
Posted in: Pharma News | 0 Comments »
Read the full story
BREAKING NEWS: Merck to shutter eight R&D facilities in global restructuring
Thursday, July 8th, 2010
Driven by a need to cut back after swallowing Schering-Plough while relying more on external development collaborations, Merck today spelled out long-awaited plans to shutter eight R&D centers around the globe, including facilities in Cambridge, MA and Montreal. In a release issued this morning, Merck said it would close research operations in Montreal, Canada; Boxmeer (Nobilon facility only), Oss, and Schaijk, Netherlands; Odense, Denmark; Waltrop, Germany; Newhouse, Scotland; and Cambridge (Kendall Square), MA. Merck’s manufacturing division, meanwhile, will shrink from 91 facilities at the close of the merger to 77 facilities.
Posted in: Pharma News | 0 Comments »
Read the full story
Merck to shutter eight R&D facilities in global restructuring
Thursday, July 8th, 2010
Driven by a need to cut back after swallowing Schering-Plough while relying more on external development collaborations, Merck today spelled out long-awaited plans to shutter eight R&D centers around the globe, including facilities in Cambridge, MA and Montreal. In a release issued this morning, Merck said it would close research operations in Montreal, Canada; Boxmeer (Nobilon facility only), Oss, and Schaijk, Netherlands; Odense, Denmark; Waltrop, Germany; Newhouse, Scotland; and Cambridge (Kendall Square), MA. Merck’s manufacturing division, meanwhile, will shrink from 91 facilities at the close of the merger to 77 facilities .
Posted in: Pharma News | 0 Comments »
Read the full story
Does Eli Lilly Make for an Intelligent Investment or Intelligent Speculation Today?
Tuesday, June 29th, 2010
Bud Labitan submits Eli Lilly ( LLY ) discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries
Posted in: Pharma News | 0 Comments »
Read the full story
Eli Lilly: This Big Pharma Needs to Get Better
Monday, June 28th, 2010
Steve Alexander submits: Eli Lilly ( LLY ) is one of the largest of the “big pharmaceutical” companies, focusing especially on the clinical areas of the nervous system, endocrine system (hormones), cancer, and the cardiovascular system (heart and lungs). The firm also has a substantial veterinary drug business. Lilly’s largest and most important drug is Zyprexa, which is used to treat schizophrenia and bipolar disorders.
Posted in: Pharma News | 0 Comments »
Read the full story
How much is your reputation worth ?
Wednesday, March 24th, 2010
A cardiologist released a paper on the cardiovascular safety on the TZD’s (Avandia). These cardiologists have few conflicts on interest, and take an incredibly balanced approach to the data surrounding the use of Avandia by patients. In summary they found; -there is not enough evidence to say Actos is any safer than Avandia.
Posted in: DTC | 0 Comments »
Read the full story
Avandia: Off the Market or Not?
Monday, February 22nd, 2010
The Senate report that leaked on Avandia (rosiglitazone) over the weekend has made plenty of headlines . It quotes an internal FDA report that recommends flatly that the drug be removed from the market, since its beneficial effects can be achieved by use of the competing PPAR drug Actos (pioglitazone), which doesn’t seem to have the same cardiovascular risks. The two drugs have been compared (retrospectively) head to head, and Avandia definitely seems to have come out as inferior due to safety concerns.
Posted in: Clinical Trials | 0 Comments »
Read the full story
Tracleer – Stand
Sunday, September 20th, 2009
In Pulmonary arterial hypertension (PAH) WHO Class III or IV Tracleer stands alone Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. More on Wikipedia Brand name: Tracleer Generic name/category: Bosentan, Endothelin receptor antagonists Company: Actelion Country/Market: USA, North America Indication(s)/use: Pulmonary arterial hypertension (PAH) Target: Healthcare Professionals (HCP) Tagline: A cornerstone of oral therapy Medium: Print ad Size/duration: single-page Publication/Aired: Chest – September 2009 To see all of this brand's ads on AdPharm, click here 1 views Sep 19, 2009 Visit AdPharm.net for more pharmaceutical ads
Posted in: Pharma Ads | 0 Comments »
Read the full story
Tracleer – Goes beyond
Sunday, September 20th, 2009
In Pulmonary arterial hypertension (PAH) WHO Class III or IV Tracleer goes beyond symptomatic relief Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. More on Wikipedia Brand name: Tracleer Generic name/category: Bosentan, Endothelin receptor antagonists Company: Actelion Country/Market: USA, North America Indication(s)/use: Pulmonary arterial hypertension (PAH) Target: Healthcare Professionals (HCP) Tagline: A cornerstone of oral therapy Medium: Print ad Size/duration: single-page Publication/Aired: Chest – August 2009 To see all of this brand's ads on AdPharm, click here 2 views Sep 19, 2009 Visit AdPharm.net for more pharmaceutical ads
Posted in: Pharma Ads | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice